• OPEN AN ACCOUNT
Indian Indices
Nifty
26,215.55 10.25
(0.04%)
Sensex
85,720.38 110.87
( 0.13%)
Bank Nifty
59,737.30 209.25
( 0.35%)
Nifty IT
37,446.30 81.70
( 0.22%)
Global Indices
Nasdaq
47,439.25 305.79
(0.65%)
Dow Jones
6,833.01 46.13
(0.68%)
Hang Seng
50,154.28 595.21
(1.20%)
Nikkei 225
9,690.34 80.81
(0.84%)
Forex
USD-INR
89.15 -0.06
(-0.06%)
EUR-INR
102.93 0.12
(0.12%)
GBP-INR
117.17 0.31
(0.26%)
JPY-INR
0.57 0.00
(0.22%)

EQUITY - MARKET SCREENER

Sun Pharmaceutical Industries Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524715
INE044A01036
99.2482659
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SUNPHARMA
92.65
433043.97
EPS(TTM)
Face Value()
Div & Yield %
19.48
1
0.89
 

Astrazeneca Pharma and Sun Pharma form second brand partnership
Nov 17,2025
Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.